Reviewed,
UniProtKB/Swiss-Prot P29466 (CASP1_HUMAN)
Last modified
November 25, 2008.
Version 103.
History...
Clusters with 100%,
90%,
50% identity |
Documents (5) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Caspase-1 Short name=CASP-1 EC=3.4.22.36 Alternative name(s): Interleukin-1 beta convertase Short name=IL-1BC Interleukin-1 beta-converting enzyme Short name=IL-1 beta-converting enzyme Short name=ICE p45 Cleaved into the following 2 chains: 1- Recommended name: Caspase-1 subunit p20 2- Recommended name: Caspase-1 subunit p10 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 404 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis. |
| Catalytic activity | Strict requirement for an Asp residue at position P1 and has a preferred cleavage sequence of Tyr-Val-Ala-Asp-|-. |
| Enzyme regulation | Specifically inhibited by the cowpox virus Crma protein. |
| Subunit structure | Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 20 kDa (p20) and a 10 kDa (p10) subunit. The p20 subunit can also form a heterodimer with the epsilon isoform which then has an inhibitory effect. May be a component of the inflammasome, a protein complex which also includes PYCARD, CARD8 and NALP2 and whose function would be the activation of proinflammatory caspases. Interacts with INCA. |
| Subcellular location | |
| Tissue specificity | Expressed in larger amounts in spleen and lung. Detected in liver, heart, small intestine, colon, thymus, prostate, skeletal muscle, peripheral blood leukocytes, kidney and testis. No expression in the brain. |
| Post-translational modification | The two subunits are derived from the precursor sequence by an autocatalytic mechanism. |
| Sequence similarities | Belongs to the peptidase C14 family. Contains 1 CARD domain. |
Ontologies
Keywords | |
|---|---|
| Biological process | Apoptosis |
| Cellular component | Cytoplasm |
| Coding sequence diversity | Alternative splicing |
| Molecular function | Hydrolase Protease Thiol protease |
| PTM | Zymogen |
| Technical term | 3D-structure Direct protein sequencing |
Gene Ontology (GO) | |
| Biological process | positive regulation of I-kappaB kinase/NF-kappaB cascade Inferred from expression pattern. Source: UniProtKB proteolysis Ref.7Inferred from direct assay. Source: UniProtKB |
| Cellular component | cytoplasm Inferred from electronic annotation. Source: UniProtKB-KW nucleusInferred from direct assay. Source: HPA |
| Molecular function | caspase activator activity Traceable author statement. Source: ProtInc cysteine-type endopeptidase activityTraceable author statement. Source: ProtInc protein binding Ref.8Inferred from physical interaction. Source: UniProtKB |
| Complete GO annotation... | |
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| FGF2 | P09038 | 1 | EBI-516667,EBI-977447 | |
| IL1A | P01583 | 3 | EBI-516667,EBI-1749782 | |
| NLRC4 | Q9NPP4 | 1 | EBI-516667,EBI-1222527 | |
| NLRP1 | Q9C000 | 1 | EBI-516667,EBI-1220518 |
Alternative products
| This entry describes 6 isoforms produced by alternative splicing. [Align] [Select] Notes: Additional isoforms seem to exist. | ||||||
| Isoform Alpha (identifier: P29466-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform Beta (identifier: P29466-2) The sequence of this isoform differs from the canonical sequence as follows: 92-112: Missing. | ||||||
| Isoform Gamma (identifier: P29466-3) The sequence of this isoform differs from the canonical sequence as follows: 20-112: Missing. | ||||||
| Isoform Delta (identifier: P29466-4) The sequence of this isoform differs from the canonical sequence as follows: 20-112: Missing. 288-335: Missing. | ||||||
| Notes: Apoptosis inactive. | ||||||
| Isoform Epsilon (identifier: P29466-5) The sequence of this isoform differs from the canonical sequence as follows: 20-335: Missing. | ||||||
| Notes: Apoptosis inactive. | ||||||
| Isoform Zeta (identifier: P29466-6) The sequence of this isoform differs from the canonical sequence as follows: 1-39: Missing. | ||||||
| Notes: Can promote apoptosis. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Propeptide | 1 – 119 | 119 | PRO_0000004521 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chain | 120 – 297 | 178 | Caspase-1 subunit p20 | PRO_0000004522 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Propeptide | 298 – 316 | 19 | PRO_0000004523 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chain | 317 – 404 | 88 | Caspase-1 subunit p10 | PRO_0000004524 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 1 – 91 | 91 | CARD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sites | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Active site | 237 | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Active site | 285 | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 1 – 39 | 39 | Missing in isoform Zeta. | VSP_021670 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 20 – 335 | 316 | Missing in isoform Epsilon. | VSP_000797 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 20 – 112 | 93 | Missing in isoform Gamma and isoform Delta. | VSP_000799 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 92 – 112 | 21 | Missing in isoform Beta. | VSP_000798 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 288 – 335 | 48 | Missing in isoform Delta. | VSP_000800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 285 | 1 | C → A or S: Loss of activity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 319 | 1 | K → R in BAD97223. Ref.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 402 | 1 | P → L in BAD97223. Ref.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 129 – 132 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 138 – 147 | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 158 – 160 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 164 – 169 | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 174 – 176 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 182 – 195 | 14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 199 – 205 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 208 – 219 | 12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 222 – 226 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 230 – 236 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 242 – 244 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 250 – 252 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 258 – 265 | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 267 – 269 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 271 – 273 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 278 – 284 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 286 – 289 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 292 – 296 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 318 – 324 | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 326 – 333 | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 343 – 345 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 348 – 360 | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 361 – 363 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 366 – 376 | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 388 – 392 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes." Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., Miller D.K., Molineaux S.M., Weidner J.R., Aunins J., Elliston K.O., Ayala J.M., Casano F.J., Chin J., Ding G.J.-F., Egger L.A., Gaffney E.P., Limjuco G. Tocci M.J.Nature 356:768-774(1992) [PubMed: 1574116] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, ACTIVE SITE. |
| [2] | "Molecular cloning of the interleukin-1 beta converting enzyme." Cerretti D.P., Kozlosky C.J., Mosley B., Nelson N., van Ness K., Greenstreet T.A., March C.J., Kronheim S.R., Druck T., Cannizzaro L.A., Huebner K., Black R.A. Science 256:97-100(1992) [PubMed: 1373520] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE OF 120-142. |
| [3] | "Caspase-1 zeta, a new splice variant of caspase-1 gene." Feng Q., Li P., Leung P.C.K., Auersperg N. Genomics 84:587-591(2004) [PubMed: 15498465] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA), FUNCTION, MUTAGENESIS OF CYS-285, ALTERNATIVE SPLICING, TISSUE SPECIFICITY. |
| [4] | Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S. Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA). |
| [5] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GAMMA), NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4-404 (ISOFORM BETA). Tissue: Testis. |
| [6] | "Purification of interleukin-1 beta converting enzyme, the protease that cleaves the interleukin-1 beta precursor." Kronheim S.R., Mumma A., Greenstreet T., Glackin P.J., Van Ness K., March C.J., Black R.A. Arch. Biochem. Biophys. 296:698-703(1992) [PubMed: 1321594] [Abstract] Cited for: PROTEIN SEQUENCE OF 120-142. |
| [7] | "Cloning and expression of four novel isoforms of human interleukin-1 beta converting enzyme with different apoptotic activities." Alnemri E.S., Fernandes-Alnemri T., Litwack G. J. Biol. Chem. 270:4312-4317(1995) [PubMed: 7876192] [Abstract] Cited for: ALTERNATIVE SPLICING, FUNCTION. |
| [8] | "NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder." Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. Immunity 20:319-325(2004) [PubMed: 15030775] [Abstract] Cited for: COMPONENT OF THE INFLAMMASOME. |
| [9] | "INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation." Lamkanfi M., Denecker G., Kalai M., D'hondt K., Meeus A., Declercq W., Saelens X., Vandenabeele P. J. Biol. Chem. 279:51729-51738(2004) [PubMed: 15383541] [Abstract] Cited for: INTERACTION WITH INCA. |
| [10] | "Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)2 homodimer." Walker N.P.C., Talanian R.V., Brady K.D., Dang L.C., Bump N.J., Ferenz C.R., Franklin S., Ghayur T., Hackett M.C., Hammill L.D., Herzog L., Hugunin M., Houy W., Mankovich J.A., McGuiness L., Orlewicz E., Paskind M., Pratt C.A. Wong W.W.Cell 78:343-352(1994) [PubMed: 8044845] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS), SUBUNIT. |
| [11] | "A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE)." Rano T.A., Timkey T., Peterson E.P., Rotonda J., Nicholson D.W., Becker J.W., Chapman K.T., Thornberry N.A. Chem. Biol. 4:149-155(1997) [PubMed: 9190289] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS). |
| [12] | "Peptide based interleukin-1 beta converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex." Okamoto Y., Anan H., Nakai E., Morihira K., Yonetoku Y., Kurihara H., Sakashita H., Terai Y., Takeuchi M., Shibanuma T., Isomura Y. Chem. Pharm. Bull. 47:11-21(1999) [PubMed: 9987822] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH INHIBITORS. |
| [13] | "Crystal structures of a ligand-free and malonate-bound human caspase-1: implications for the mechanism of substrate binding." Romanowski M.J., Scheer J.M., O'Brien T., McDowell R.S. Structure 12:1361-1371(2004) [PubMed: 15296730] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 120-404 OF MUTANT ALA-285. |
| + | Additional computationally mapped references. |

Clusters with